With momentum from FDA OK, SK Biopharma to breath new life into Korean biotech with $850M IPO — report
SK Life Science’s recent success at the FDA is setting its parent company nicely for a $850 million IPO in Korea, the Financial Times reported.
The group — a subsidiary of the conglomerate SK Holdings dedicated to drug discovery and development — filed its preliminary application to the Korea Exchange late last month. But the recent US approval for epilepsy drug Xcopri, or cenobamate, raised analysts’ expectations on the amount they can bag.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.